Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Repros Therapeutics (RPRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 11,183
  • Shares Outstanding, K 29,430
  • Annual Sales, $ 50 K
  • Annual Income, $ -17,270 K
  • 36-Month Beta 0.56
  • Price/Sales 241.26
  • Price/Cash Flow 0.00
  • Price/Book 6.35
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.73
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/08/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.30 +26.67%
on 07/17/17
0.64 -40.53%
on 07/12/17
+0.04 (+11.76%)
since 06/20/17
3-Month
0.30 +26.67%
on 07/17/17
1.07 -64.49%
on 04/21/17
-0.63 (-62.38%)
since 04/20/17
52-Week
0.30 +26.67%
on 07/17/17
2.48 -84.68%
on 08/15/16
-1.42 (-78.89%)
since 07/20/16

Most Recent Stories

More News
Repros' Proellex Stays on Partial Clinical Hold, Shares Fall

Repros Therapeutics Inc. (RPRX) announced that its pipeline candidate Proellex which is being evaluated for uterine fibroids will remain on partial clinical hold.

ENZ : 11.55 (-0.43%)
BAYRY : 130.3700 (+1.43%)
RPRX : 0.38 (unch)
ABBV : 73.99 (+1.68%)
INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Repros Therapeutics Inc.

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Repros Therapeutics Inc. ("Repros" or the "Company")...

RPRX : 0.38 (unch)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics Inc. (RPRX)

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repros Therapeutics Inc. ("Repros" or the "Company") (NASDAQ: RPRX). Such investors...

RPRX : 0.38 (unch)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repros Therapeutics, Inc. - RPRX

Pomerantz LLP is investigating claims on behalf of investors of Repros Therapeutics, Inc. ("Repros" or the "Company") (NASDAQ: RPRX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

RPRX : 0.38 (unch)
Repros Announces Pricing of $3.0 Million Public Offering Of Common Stock And Warrants To Purchase Common Stock

Repros Therapeutics Inc (Nasdaq:RPRX) ("Repros" or the "Company"), announced today that it has entered into an underwriting agreement to sell in a public offering 2,744,125 shares of the Company's common...

RPRX : 0.38 (unch)
Repros Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock

Repros Therapeutics Inc. (Nasdaq:RPRX) ("Repros" or the "Company") today announced that it intends to offer primary shares of its common stock and warrants to purchase shares of its common stock in an...

RPRX : 0.38 (unch)
Repros Therapeutics Inc.(R) Reports First Quarter 2017 Financial Results

Repros Therapeutics Inc. (Nasdaq:RPRX) today announced financial results for the first quarter ended March 31, 2017.

RPRX : 0.38 (unch)
What's in the Cards for Repros (RPRX) this Earnings Season?

Repros Therapeutics Inc. (RPRX) is expected to report first-quarter 2017 results this month. Let's see how things are shaping up for this quarter.

RPRX : 0.38 (unch)
AUPH : 6.72 (-0.88%)
IMDZ : 9.20 (+0.55%)
FGEN : 35.25 (+1.59%)
Repros Announces the Issuance of New U.S. Patent Relating to Treatment Using Off Drug Intervals For Certain Uterine Conditions

Repros Therapeutics Inc.(R) (Nasdaq:RPRX) today announced the issuance of a new patent, U.S. Patent number 9,616,074 (the '074 patent), that bolsters the Company's intellectual property relating to Proellex(R)...

RPRX : 0.38 (unch)
Repros' Proellex Continues to be Under Partial Clinical Hold

Repros Therapeutics (RPRX) announced that the FDA will continue to maintain partial clinical hold on its pipeline candidate Proellex for uterine fibroids indication as the agency internally reviews data...

RPRX : 0.38 (unch)
PGNX : 6.63 (-2.07%)
NBIX : 48.07 (+0.71%)
ABBV : 73.99 (+1.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Zonagen Inc. is a biopharmaceutical company engaged in the development of products for the human reproductive system, including sexual dysfunction, vaccine adjuvants, products for fertility and female health as well as urological applications, specifically prostate cancer. Zonagen's products to treat...

See More

Support & Resistance

2nd Resistance Point 0.42
1st Resistance Point 0.40
Last Price 0.38
1st Support Level 0.36
2nd Support Level 0.34

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.